دورية أكاديمية
Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.
| العنوان: | Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC. |
|---|---|
| المؤلفون: | Yoon HA; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA., Bartash R; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA., Gendlina I; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA., Rivera J; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.; Department of Microbiology and Immunology and., Nakouzi A; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.; Department of Microbiology and Immunology and., Bortz RH 3rd; Department of Microbiology and Immunology and., Wirchnianski AS; Department of Microbiology and Immunology and.; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA., Paroder M; Department of Pathology and., Fehn K; Department of Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA., Serrano-Rahman L; Department of Pathology and., Babb R; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.; Department of Microbiology and Immunology and., Sarwar UN; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA., Haslwanter D; Department of Microbiology and Immunology and., Laudermilch E; Department of Microbiology and Immunology and., Florez C; Department of Microbiology and Immunology and.; Department of Chemistry and Life Science, United States Military Academy at West Point, West Point, New York, USA., Dieterle ME; Department of Microbiology and Immunology and., Jangra RK; Department of Microbiology and Immunology and., Fels JM; Department of Microbiology and Immunology and., Tong K; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA., Mariano MC; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA., Vergnolle O; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA., Georgiev GI; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA., Herrera NG; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA., Malonis RJ; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA., Quiroz JA; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA., Morano NC; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA., Krause GJ; Department of Developmental & Molecular Biology.; Institute for Aging Research, and., Sweeney JM; Department of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, New York, USA., Cowman K; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA., Allen S; Albert Einstein College of Medicine, Bronx, New York, USA., Annam J; Albert Einstein College of Medicine, Bronx, New York, USA., Applebaum A; Albert Einstein College of Medicine, Bronx, New York, USA., Barboto D; Albert Einstein College of Medicine, Bronx, New York, USA., Khokhar A; Albert Einstein College of Medicine, Bronx, New York, USA., Lally BJ; Albert Einstein College of Medicine, Bronx, New York, USA., Lee A; Albert Einstein College of Medicine, Bronx, New York, USA., Lee M; Albert Einstein College of Medicine, Bronx, New York, USA., Malaviya A; Albert Einstein College of Medicine, Bronx, New York, USA., Sample R; Albert Einstein College of Medicine, Bronx, New York, USA., Yang XA; Albert Einstein College of Medicine, Bronx, New York, USA., Li Y; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA., Ruiz R; Network Performance Group, Montefiore Medical Center, Bronx, New York, USA.; Division of Hospital Medicine, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA., Thota R; Network Performance Group, Montefiore Medical Center, Bronx, New York, USA., Barnhill J; Department of Chemistry and Life Science, United States Military Academy at West Point, West Point, New York, USA., Goldstein DY; Department of Pathology and., Uehlinger J; Department of Pathology and., Garforth SJ; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA., Almo SC; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.; Department of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, New York, USA., Lai JR; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA., Gil MR; Department of Pathology and., Fox AS; Department of Pathology and., Chandran K; Department of Microbiology and Immunology and., Wang T; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA., Daily JP; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.; Department of Microbiology and Immunology and., Pirofski LA; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.; Department of Microbiology and Immunology and. |
| المصدر: | JCI insight [JCI Insight] 2021 Feb 22; Vol. 6 (4). Date of Electronic Publication: 2021 Feb 22. |
| نوع المنشور: | Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]- |
| مواضيع طبية MeSH: | Antibodies, Neutralizing/*administration & dosage , Antibodies, Viral/*administration & dosage , COVID-19/*therapy , SARS-CoV-2/*immunology, Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; COVID-19/immunology ; COVID-19/mortality ; COVID-19/virology ; Female ; Hospital Mortality ; Humans ; Immunization, Passive/methods ; Male ; Middle Aged ; New York City/epidemiology ; Propensity Score ; Retrospective Studies ; Spike Glycoprotein, Coronavirus/immunology ; Treatment Outcome ; COVID-19 Serotherapy |
| مستخلص: | Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as a treatment for coronavirus disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200 mL of CCP with a spike protein IgG titer ≥ 1:2430 (median 1:47,385) within 72 hours of admission with propensity score-matched controls cared for at a medical center in the Bronx, between April 13 and May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroid use, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared with matched controls, CCP recipients less than 65 years had 4-fold lower risk of mortality and 4-fold lower risk of deterioration in oxygenation or mortality at day 28. For CCP recipients, pretransfusion spike protein IgG, IgM, and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients less than 65 years, but data from controlled trials are needed to validate this finding and establish the effect of aging on CCP efficacy. |
| التعليقات: | Update of: medRxiv. 2020 Dec 04;:. (PMID: 33300012) |
| References: | J Hosp Med. 2020 Aug;15(8):489-493. (PMID: 32804611) JAMA Netw Open. 2020 Sep 1;3(9):e2022310. (PMID: 32965502) Chest. 2020 Jul;158(1):e9-e13. (PMID: 32243945) JAMA Intern Med. 2020 Aug 1;180(8):1043-1044. (PMID: 32383754) Emerg Infect Dis. 2016 Sep;22(9):1554-61. (PMID: 27532807) N Engl J Med. 2021 Feb 18;384(7):610-618. (PMID: 33406353) Open Forum Infect Dis. 2020 Sep 01;7(10):ofaa401. (PMID: 33088846) J Clin Virol. 2004 Dec;31(4):304-9. (PMID: 15494274) Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877) Mayo Clin Proc. 2020 Sep;95(9):1888-1897. (PMID: 32861333) Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. (PMID: 32221519) N Engl J Med. 2021 Feb 25;384(8):693-704. (PMID: 32678530) Lancet Infect Dis. 2021 Feb;21(2):203-212. (PMID: 33091374) Int J Infect Dis. 2020 Dec;101:194-200. (PMID: 32987177) J Clin Invest. 2020 Sep 1;130(9):4791-4797. (PMID: 32525844) Cell Host Microbe. 2020 Sep 9;28(3):486-496.e6. (PMID: 32738193) Blood. 2020 Aug 6;136(6):755-759. (PMID: 32573724) Clin Infect Dis. 2011 Feb 15;52(4):447-56. (PMID: 21248066) Nat Med. 2020 Nov;26(11):1708-1713. (PMID: 32934372) J Clin Invest. 2020 Oct 1;130(10):5235-5244. (PMID: 32634129) Infez Med. 2020 Sep 1;28(3):357-366. (PMID: 32920571) ACS Omega. 2020 Dec 21;6(1):85-102. (PMID: 33458462) Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6. (PMID: 15616839) J Clin Virol. 2020 Jun;127:104388. (PMID: 32361326) Am J Pathol. 2021 Jan;191(1):90-107. (PMID: 33157066) N Engl J Med. 2020 May 21;382(21):2049-2055. (PMID: 32202722) N Engl J Med. 2021 Jan 21;384(3):229-237. (PMID: 33113295) N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013) Cell. 2021 Jan 21;184(2):476-488.e11. (PMID: 33412089) Lancet. 2020 May 30;395(10238):1673-1676. (PMID: 32401716) Nat Med. 2020 Jun;26(6):845-848. (PMID: 32350462) J Infect Dis. 2015 Jan 1;211(1):80-90. (PMID: 25030060) Cell Mol Immunol. 2020 Jul;17(7):773-775. (PMID: 32467617) MMWR Morb Mortal Wkly Rep. 2020 Jul 17;69(28):923-929. (PMID: 32673298) JAMA. 2020 Apr 28;323(16):1582-1589. (PMID: 32219428) Blood. 2020 Aug 6;136(6):759-762. (PMID: 32559767) Ann Intern Med. 2006 Oct 17;145(8):599-609. (PMID: 16940336) JAMA. 2020 Oct 6;324(13):1330-1341. (PMID: 32876694) JCI Insight. 2021 Mar 22;6(6):. (PMID: 33571168) JAMA. 2020 Jun 2;323(21):2192-2195. (PMID: 32347898) J Korean Med Sci. 2020 Apr 13;35(14):e149. (PMID: 32281317) Science. 2020 Dec 4;370(6521):1227-1230. (PMID: 33115920) Signal Transduct Target Ther. 2020 Mar 27;5(1):33. (PMID: 32296069) J Clin Invest. 2020 Apr 1;130(4):1545-1548. (PMID: 32167489) J Med Virol. 2020 Oct;92(10):1890-1901. (PMID: 32293713) J Virol. 2011 Oct;85(20):10582-97. (PMID: 21775467) Nat Microbiol. 2020 Apr;5(4):536-544. (PMID: 32123347) Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264) Front Immunol. 2020 May 01;11:827. (PMID: 32425950) Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. (PMID: 32253318) Clin Infect Dis. 2021 Jul 1;73(1):e208-e214. (PMID: 33038227) Emerg Infect Dis. 2020 Jul;26(7):1478-1488. (PMID: 32267220) BMJ. 2020 Oct 22;371:m3939. (PMID: 33093056) JAMA. 2020 Aug 4;324(5):460-470. (PMID: 32492084) EClinicalMedicine. 2020 Aug;25:100455. (PMID: 32838233) Lancet Respir Med. 2020 Jul;8(7):659-661. (PMID: 32437646) N Engl J Med. 2020 Nov 5;383(19):1813-1826. (PMID: 32445440) N Engl J Med. 2021 Feb 18;384(7):619-629. (PMID: 33232588) Geroscience. 2020 Apr;42(2):505-514. (PMID: 32274617) Am J Pathol. 2020 Nov;190(11):2290-2303. (PMID: 32795424) |
| معلومات مُعتمدة: | F30 AI150055 United States AI NIAID NIH HHS; T32 GM007491 United States GM NIGMS NIH HHS; T32 GM007288 United States GM NIGMS NIH HHS; P30 CA013330 United States CA NCI NIH HHS; UL1 TR002377 United States TR NCATS NIH HHS; R21 AI141367 United States AI NIAID NIH HHS; R01 AI143453 United States AI NIAID NIH HHS; R01 AI125462 United States AI NIAID NIH HHS; UL1 TR001073 United States TR NCATS NIH HHS; P30 AI124414 United States AI NIAID NIH HHS; UL1 TR002556 United States TR NCATS NIH HHS; U19 AI142777 United States AI NIAID NIH HHS; R01 AI145024 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: COVID-19; Immunoglobulins; Infectious disease |
| المشرفين على المادة: | 0 (Antibodies, Neutralizing) 0 (Antibodies, Viral) 0 (Spike Glycoprotein, Coronavirus) |
| تواريخ الأحداث: | Date Created: 20210121 Date Completed: 20210308 Latest Revision: 20240216 |
| رمز التحديث: | 20240216 |
| مُعرف محوري في PubMed: | PMC7934933 |
| DOI: | 10.1172/jci.insight.142270 |
| PMID: | 33476300 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2379-3708 |
|---|---|
| DOI: | 10.1172/jci.insight.142270 |